The effect of pirfenidone on impaired lung function in patients with idiopathic pulmonary fibrosis (IPF) from Czech IPF registry
| Autor: | Jana Psikalova, Monika Zurkova, Vladimir Rihak, Vitezslav Kolek, Tomas Snizek, Jaroslav Lnenicka, Martina Doubková, Martina Plačková, Vladimira Lostakova, Vladimir Bartos, Martina Vasakova, Pavlína Lisá, Frantisek Petrik, Renata Králová, Richard Tyl, Jana Strenková, Radka Bittenglova, Gustav Ondrejka, Michal Svoboda, Eva Kriegova, Hana Suldova, Ilona Binková, Ladislav Lacina, Martina Sterclova, Jiri Homolka, Jan Kervitzer |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Lung business.industry Retrospective cohort study Pirfenidone respiratory system 030204 cardiovascular system & hematology medicine.disease Gastroenterology respiratory tract diseases 3. Good health Surgery 03 medical and health sciences Idiopathic pulmonary fibrosis FEV1/FVC ratio 0302 clinical medicine medicine.anatomical_structure 030228 respiratory system DLCO Internal medicine medicine In patient business Lung function medicine.drug |
| Zdroj: | 1.5 Diffuse Parenchymal Lung Disease. |
| Popis: | Aims and objectives: The aim of the study was to compare the annual declineof lung functions during treatment with pirfenidone in comparison to triple-combination and other treatment modalities in Czech patients with IPF. Methods: Currently, the Czech IPF registry consists of 517 patients diagnosed with IPF-UIP. Our retrospective study included 72 patients treated with pirfenidone, 27 with triple-combination and 97 received other treatment modalities. To estimate the annual change of FVC and TLCO, a linear regression model with mixed effects was used. p -value Results: The comparison of changes in lung function over a 1-year follow-up showed lower decrease in the predicted value (PV) of FVC in pirfenidon group than in triple-combination (-0.093 vs -0.222, p -value=0.026) and trend to lower decrease in comparison to other treatment modalities (-0.093 vs -0.162, p -value=0.082). Also, a 1-year decrease in the PV of a TLCO was smaller in pirfenidon group than in triple-combination (0.221 vs -0.453, p -value=0.096) and other modalities group (-0.221 vs -0.389, p -value=0.082); however the decrease did reach significancy between studied groups. Conclusion: In Czech IPF patients, pirfenidone administration was associated with the lower decrease in lung function (FVC, TLCO) comparing with other treatment modalities. Our observation supports current recommendation of pirferidon for mild and moderate IPF. Supported by IGA_LF_2016_011. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|